Completed NA INTERVENTIONAL NCT00601562

Bioequivalency Study of Zidovudine Under Fed Conditions

A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fed Conditions

Sponsor: Roxane Laboratories

Conditions HIV Infections

Interventions Zidovudine

Updated 7 times since 2017 Last updated: Jan 19, 2018 Started: Jun 30, 2003 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00601562, this NA trial focuses on HIV Infections and remains completed. Sponsored by Roxane Laboratories, it has been updated 7 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2018 [monthly]

Completed NA

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxane Laboratories

Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States